RTP Mobile Logo
RTP TV: Part II — Colorectal Cancer
Released August 2012

The second seminar of our online, integrated educational course explores topics relevant to the treatment of colorectal cancer. Originally held on July 26, 2012, Part II features Drs Richard M Goldberg and Axel Grothey.

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of colorectal cancer.
    Cancer of the colon and rectum is the fourth most frequently diagnosed cancer and the second most common cause of death among all neoplasms in both men and women in the United States, accounting for approximately 9% of all cancer deaths. Current therapeutic management of colorectal cancer is dependent on tumor stage at the time of initial diagnosis, status of surgical margins (R0, R1, R2), patient performance status, age, prior treatment exposure and sites of metastasis for those with disease recurrence or de novo advanced cancer. Although these variables are helpful in guiding selection of treatment, the introduction of novel biomarkers, multigene signatures and molecular-targeted systemic agents has significantly refined the clinical algorithm, such that individualized therapeutic approaches have become the standard. This rapid paradigm shift presents a challenge to practicing oncologists who must grapple with the presentation of ambiguous data sets and their immediate impact on treatment decisions. This program uses a review of recent publications and presentations, faculty cases and Q&A to assist medical oncologists, hematology-oncology fellows and other healthcare providers with the formulation of up-to-date clinical management strategies.
    • Compare and contrast the clinical relevance of recent pivotal colorectal cancer research results, as published in peer-reviewed journals and/or presented at major oncology conferences.
    • Appropriately integrate biomarkers and multigene assays when communicating prognosis and treatment options to patients with early-stage colon cancer.
    • Identify patient and tumor characteristics that enable the safe and efficacious use of combination chemobiologic regimens for advanced colorectal cancer.
    • Effectively apply the results of practice-changing clinical research in the selection and sequencing of chemobiologic regimens for patients with metastatic colorectal cancer.
    • Recall new data with investigational agents demonstrating promising activity in colorectal cancer.
    • Employ case-based learning to refine or validate your existing colorectal cancer-specific treatment algorithms.
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
    Richard M Goldberg, MD
    Professor of Medicine
    OSUCCC James Cancer Hospital and
    Richard J Solove Research Institute
    Klotz Family Chair in Cancer Research
    The Ohio State University
    Columbus, Ohio
    Advisory Committee: Bayer HealthCare Pharmaceuticals; Consulting Agreements: Genomic Health Inc, Sanofi; Data and Safety Monitoring Board: Lilly USA LLC.
    Axel Grothey, MD
    Professor of Oncology
    Department of Medical Oncology
    Mayo Clinic
    Rochester, Minnesota
    Paid Research: Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech BioOncology.
    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.
    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
    This activity is supported by educational grants from Genentech BioOncology, Regeneron Pharmaceuticals and Sanofi.
    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio
    Last review date: August 2012
    Expiration date: August 2013

Acknowledge and close

Watch Video
(WiFi is recommended for best performance):